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Summary
The membrane fatty acid unsaturation hypothesis of aging and
longevity is experimentally tested for the first time in mammals.
Lifelong treatment of mice with the b1-blocker atenolol increased
the amount of the extracellular-signal-regulated kinase signaling
protein and successfully decreased one of the two traits appro-
priately correlating with animal longevity, the membrane fatty
acid unsaturation degree of cardiac and skeletal muscle mitochon-
dria, changing their lipid profile toward that present inmuchmore
longer-livedmammals. Thiswasmainly due to decreases in 22:6n-3
and increases in 18:1n-9 fatty acids. The atenolol treatment also
lowered visceral adiposity (by 24%), decreased mitochondrial
protein oxidative, glycoxidative, and lipoxidative damage in both
organs, and lowered oxidative damage in heart mitochondrial
DNA. Atenolol also improved various immune (chemotaxis and
natural killer activities) and behavioral functions (equilibrium,
motor coordination, andmuscular vigor). It also totally or partially
prevented the aging-related detrimental changes observed in
mitochondrial membrane unsaturation, protein oxidative modifi-
cations, and immune and behavioral functions, without changing
longevity. The controls reached 3.93 years of age, a substantially
higher maximum longevity than the best previously described for
this strain (3.0 years). Side effects of the drug could havemasked a
likely lowering of the endogenous aging rate induced by the
decrease inmembrane fatty acid unsaturation.We conclude that it
is atenolol that failed to increase longevity, and likely not the
decrease in membrane unsaturation induced by the drug.
Key words: aging; atenolol; fatty acid unsaturation; heart
rate; longevity; oxidative stress.
Abbreviations
AASA aminoadipic semialdehydes
AIF apoptosis-inducing factor
AT atenolol
CEL carboxyethyl-lysine
CML carboxymethyl-lysine
DBI double bond index
GSA glutamic semialdehydes
MDAL malondialdehyde-lysine
mitROS mitochondrial reactive oxygen species
mtDNA mitochondrial DNA
p-ERK phosphorylated extracellular-signal-regulated kinase
PI peroxidizability index
8-oxodG 8-oxo-7,8-dihydro-2′deoxyguanosine
Introduction
Only two known parameters appropriately correlate with animal
longevity across species – the rate of mitochondrial reactive oxygen
species production (mitROSp) and the membrane fatty acid unsaturation
degree. Long-lived mammals and birds show a low rate of mitROS
generation (reviewed in Barja, 2013) and have cellular membranes with a
low degree of fatty acid unsaturation (Pamplona et al., 1996, 2002;
Hulbert et al., 2007; Naudi et al., 2011). These two traits are funda-
mental for the mitochondrial free radical theory of aging (Harman, 1972;
Barja, 2013). The low mitROSp of long-lived species decreases oxidative
damage to key molecules such as mtDNA (Barja & Herrero, 2000), and
their low membrane fatty acid unsaturation diminishes the intensity of
lipid peroxidation and thus membrane and protein damage (Pamplona
et al., 2002) and the secondary generation of toxic chemicals and free
radicals (Pamplona, 2011; Zimniak, 2011).
Nevertheless, correlation does not imply causation. Experimental
approaches that can reveal causal connections of those two main traits
with aging and longevity are needed. In the case of mitROSp, it is
modified by dietary manipulations that increase mean and maximum
longevity. Dietary (Gredilla & Barja, 2005), protein (Sanz et al., 2004),
and methionine restriction (Sanz et al., 2006) decrease mitROSp
(Sanchez-Roman and Barja, 2013) and these three manipulations also
increase longevity in rats and mice and improve many health-related
parameters (Perrone et al., 2013), supporting the idea that the low
mitROSp of long-lived animals causally contributes to decreased aging
rate in long-lived animal species.
We hypothesize here that experimentally decreasing membrane fatty
acid unsaturation can prevent detrimental changes with age and
increase longevity in mammals. There are no investigations about the
lifelong effect of decreasing tissue membrane fatty acid unsaturation on
mammalian longevity and regulation of aging-related parameters.
Short-term – 2-week – investigations have shown that atenolol, a
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b1-adrenergic receptor blocker, given in drinking water, decreases
membrane fatty acid unsaturation in the heart of C57BL/6 mice
(Sanchez-Roman et al., 2010) and rats (Sanchez-Roman et al., 2014).
The extent of such decrease was almost equal to the difference in
unsaturation between mammals differing by one order of magnitude in
longevity, such as mice and cows, and it lowered cardiac protein
oxidative damage and lipoxidation (Sanchez-Roman et al., 2010). This is
interesting also because knocked-out mice for the adenylyl cyclase type 5
gene (AC5KO mice), which blocks b-adrenergic receptor signaling and
increases the Raf/MEK/ERK signaling pathway, showed increased
longevity together with lowered cardiovascular, heart, and bone aging
(Yan et al., 2007).
Taking advantage of the striking capacity of atenolol to strongly
decrease membrane unsaturation in mice, we use it here to experimen-
tally test, for the first time, the hypothesis that lowering the degree of
membrane fatty acid unsaturation in a mammal causes beneficial
changes during aging and increases longevity. Atenolol has been widely
used in humans during the last 3–4 decades to treat various cardiovas-
cular pathologies and has been classically considered a safe drug without
significant side effects. A total of 134 mice were treated or not with
atenolol in their drinking water during their whole lifespan, and the
effect on mean and maximum longevities was studied. At 18 months of
age, subgroups of 48 separated ‘pilot’ animals were used to measure
cardiovascular and other basic physiological parameters: membrane fatty
acid composition and global unsaturation; mitochondrial oxygen con-
sumption and mitROSp; amounts of respiratory complexes (I–IV) and the
complex I-related apoptosis-inducing factor (AIF); oxidative damage to
mtDNA; oxidative, glycoxidative, and lipoxidative protein modification in
heart and skeletal muscle mitochondria; and the amount of phosphor-
ylated extracellular-signaling-regulated kinase (p-ERK) to corroborate
activation of the Raf/MEK/ERK signaling pathway by the atenolol
treatment. Immunological parameters and various behavioral tests were
also performed to better estimate the general functional state of the
animals. Although it is generally thought that immune cells have almost
exclusively b-2 adrenergic receptors, there are results involving b-1
adrenergic receptor signaling in the modulation of immune responses
(Emeny et al., 2007), but their immunological relevance has been largely
unexplored and the effect of atenolol on the immune cell functions has
been scarcely studied. Concerning behavior, a few reports showed
decreased anxiety (Deary et al., 1991) and antidepressant effects
(Al-Tubuly et al., 2008) after atenolol treatment, but the impact of
atenolol on behavioral parameters has not been investigated. In the case
of the cardiovascular parameters, as an increase in mortality was
detected only in very old individuals, the measurements were repeated at
35 months of age. A group of young but mature adult control mice of
6 months of age (at sacrifice) maintained in parallel under similar
conditions to those of the lifelong control and treated animals was used
to check whether atenolol can prevent age-related changes. Heart and
skeletal muscle were selected as vital target organs because they are
among the ones most affected by the endogenous aging process and are
almost fully composed of postmitotic cells.
Results
Body and organ weights and physiological parameters
After 16 months of experimentation, the 18-month-old animals [both
Old controls and Old atenolol (AT)] had higher total weight and higher
heart, kidney, liver, and total visceral fat weight than Young ones,
whereas the weights of the spleen, brain, and hind limb skeletal muscle
were not modified by aging (results not shown). Visceral fat strongly
increased from 0.441  0.051 grams in Young to 2.31  0.20 g in Old
controls (424% increase; P < 0.00001). The long-term atenolol treat-
ment significantly decreased kidney weight by 7.6% (from 0.655 
0.016 to 0.605  0.012 g; P < 0.01) and visceral adipose tissue mass by
23.8% (from 2.31  0.20 to 1.76  0.18; P < 0.02; by a mean of
23.2% when expressed per grams of body mass), whereas total body
weight and the weight of the rest of the organs were not affected by the
treatment. No differences in food or water intake between Old and
Old-AT animals were observed after inspection once every 2 weeks.
The values of various basic physiological parameters are shown in
Table S1 (Supporting Information). Old-AT animals had significantly
lower routine metabolic rate than Young animals but showed no
significant differences compared to Old controls. Neither rectal temper-
ature, heart rate, nor the systolic, mean, and diastolic arterial pressures
showed AT- or age-related differences.
Long-life survival study
The survival curves of control and AT-treated animals are shown in
Fig. 1. No significant differences in mean, median, maximum (90%)
longevities, or total curve survival (Tables S2 and S3, Supporting
Information) were observed comparing control and AT-treated animals
(log-rank and Wilcoxon tests). The longer-lived animal in the control
group reached 1433 days of age (3.93 years), and the longer-lived AT
mouse reached 1310 days of age (3.6 years). A statistically significant
higher mortality in atenolol-treated compared to control animals was
observed between 1000 and 1275 days of age (Table S3, Supporting
Information). Due to this unexpected finding, the cardiovascular
parameters were measured again, more than 1 year after the previous
measurements (taken at 18 months of age), in very old animals. These
measurements showed that, at 35 months of age, heart rate and
systolic, mean, and diastolic blood pressures were significantly lower in
Old-AT than in Old controls (Table S4, Supporting Information).
Mitochondrial oxygen consumption and reactive oxygen
species production
Table S5 (Supporting Information) shows the mitochondrial oxygen
consumption values. The rate of oxygen consumption of heart
mitochondria in state 3 (phosphorylating) with complex I-linked
substrates (glutamate/malate) was significantly higher in Old than in
Young controls and significantly decreased in Old-AT to values similar to
those of Young mice. These differences were not present with
succinate + rotenone, a condition in which the inhibitor rotenone avoids
electrons to reach complex I by reverse electron flow from complex II. No
significant differences due to age or atenolol treatment were observed in
heart mitochondria in state 4 (resting) or in skeletal muscle mitochondria
with any substrate or mitochondrial state.
The basal rate of ROS production of heart mitochondria was not
modified by aging or the atenolol treatment with either glutamate/
malate or succinate + rotenone (Table S6, Supporting Information). The
maximum rate of heart complex I mitROS production, which was
obtained with glutamate + rotenone, was significantly higher in Old
controls (but not in Old-AT) than in Young controls. In the case of
skeletal muscle mitochondria, no age-related differences in the mitROS
generation of control mice were observed with any substrate. The
atenolol treatment significantly decreased skeletal muscle maximum
complex I mitROS generation (measured with glutamate/malate + rote-
none) of Old-AT compared to Old controls. Skeletal muscle mitROS
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production with glutamate/malate or succinate (which can come from
complex I or III) was significantly lower in Old-AT than in Young controls,
whereas mitROSp with succinate + rotenone (coming only from com-
plex III) did not change. All these results, taken together, indicate that
the decrease inmitROSp induced by atenolol takes place only at complex I.
Respiratory chain complexes and apoptosis-inducing factor
The amounts of the four respiratory chain protein complexes and AIF are
shown in Table S7 (Supporting Information). In the heart, no differences
between Old and Young controls were detected for any respiratory
complex. The atenolol treatment significantly increased the amount of
complex II in heart mitochondria. Heart complex I (30kDa subunit)
amount was significantly higher in Old-AT than in Young controls, but
no differences were observed between Old-AT and Old controls, and
heart complexes III and IV did not show AT-related differences. In skeletal
muscle, complexes II and IV decreased and complex III (FeS protein)
increased both in Old controls and in Old-AT when compared to Young
animals, whereas atenolol-related differences in old animals were not
observed for any complex. The amount of AIF protein did not show
aging- or AT-related variations either in heart or in skeletal muscle.
Membrane fatty acid unsaturation
The changes induced by aging andAT treatment on fatty acid composition
of heart mitochondria are shown in Table S8 (Supporting Information). As
a result of these changes, the global indexes of fatty acid unsaturation of
heartmitochondriawere changed (Fig. 2). Thus, aging increased the heart
mitochondria double bond index (DBI) and peroxidizability index (PI), and
atenolol decreased the DBI and PI of Old-AT animals to values similar to
those of Young controls (Fig. 2C). Quantitatively, the main fatty acids
responsible for the change in global unsaturation were 18:1n-9 and
especially 22:6n-3. The decrease in 18:1n-9 in Old controls was totally
prevented by atenolol, and the increase in 22:6n-3 induced by aging was
also totally prevented by the AT treatment (Fig. 2).
The changes induced by aging and AT treatment on fatty acid
composition of skeletal muscle mitochondria are shown in Table S9
(Supporting Information). These changes led to aging-related increases
in fatty acid unsaturation of skeletal muscle mitochondria (statistically
significant for PI) and to AT-related decreases in both DBI and PI
(Fig. 2D). In this tissue, the AT-induced decrease was so strong that the
DBI and PI decreased in Old-AT to values lower than those of Young
controls. Quantitatively, the main fatty acids responsible for the change
in global unsaturation were again 18:1n-9 and, especially, 22:6n-3
(Fig. 2). The decrease in 18:1n-9 in Old controls was totally prevented by
atenolol (Fig. 2A). The increase in 22:6n-3 induced by aging was totally
abolished in Old-AT animals, which showed levels even somewhat below
those of Young controls (Fig. 2B).
Fig. 1 Lifelong survival curves (Kaplan–Meyer survival plots) during the whole
lifespan of control and chronically atenolol-treated animals. No significant
differences in survival were observed between the two groups with the log-rank
and the Wilcoxon tests, while the higher mortality observed with atenolol between
1000 and 1275 days of age was statistically significant (see Table S3). The longest-
living control animal reached 3.93 years of age (47,1 months). Eighty-six animals
(43 per group) were used in the survival study. Raw data tables of control and
atenolol-treated animals are included in the online Supporting Information.
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Fig. 2 Global fatty acid unsaturation indexes (C, D) and the main fatty acids
responsible for their aging- and atenolol-induced modification (A, B: oleic,
18:1n-9; and docosahexaenoic, 22:6n-3 acids) in heart and skeletal muscle
mitochondria from Young control, Old control, and Old atenolol-treated mice.
Values are means  SEM from 5 to 6 (heart) or 6 (skeletal muscle) animals and are
expressed as absolute values (A, B: mol% of 18:1n-9 and 22:6n-3) or as
percentage of those in the Young controls [C, D: double bond index (DBI) and
peroxidizability index (PI)]. Control values of unsaturation indexes: 200.9  5.0
(DBI, heart); 213.6  6.7 (PI, heart); 186.9  5.2 (DBI, skeletal muscle);
185.1  6.2 (PI, skeletal muscle). For the calculation of DBI and PI values, see
the Materials and Methods section in the online Supporting Information. a*:
significantly different from Young controls; b*: significantly different from Old
controls; *P < 0.05; **P < 0.01; ***P < 0.001.
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Oxidative damage markers
Oxidative damage to heart mtDNA, measured as 8-oxodG (8-oxo-7,8-
dihydro-2′deoxyguanosine), tended to increase with aging (nonsignifi-
cant difference) and was significantly decreased by the chronic atenolol
treatment (Table S10, Supporting Information). In the case of skeletal
muscle, nonsignificant trends to higher 8-oxodG values in aged animals
were also observed, in this case both in Old control and in Old-AT when
compared with Young controls.
The values of the different kinds of protein modification markers
(protein oxidation, glycoxidation, and lipoxidation) are shown in Figs S1
and 3. In heart mitochondria, all the five markers measured, glutamic
semialdehydes (GSA), aminoadipic semialdehydes (AASA), carboxyethyl-
lysine (CEL), carboxymethyl-lysine (CML), and malondialdehyde-lysine
(MDAL), were significantly higher in Old than in Young controls (Fig. 3).
All these age-related increases were totally prevented by the atenolol
treatment, as Old-AT animals always showed lower levels than Old
controls and did not show significant differences when compared with
Young controls, except for GSA values that were even lower in Old-AT
than in Young animals.
In skeletal muscle mitochondria, the five protein markers also showed
significantly higher levels in Old than in Young control animals (Fig. S1,
Supporting Information). The age-related increases in GSA, AASA, CML,
and MDAL were totally prevented by the atenolol treatment because the
values in Old-AT were statistically lower than in Old controls and similar
to those of Young animals in all cases. Only in the case of CEL did the
decrease shown by Old-AT compared to Old controls not reach statistical
significance. However, the CEL value of Old-AT animals was statistically
similar to that of Young animals.
Extracellular-signal-regulated kinase signaling proteins
The amounts of ERK proteins are shown in Fig. 4. The atenolol treatment
significantly increased the amount of p-ERK/total ERK in heart and
skeletal muscle of Old-AT mice when compared with Old and Young
controls.
Immune function
Lymphoproliferation of spleen leukocytes (basal, cpm, and percentage of
stimulation in proliferation in response to the mitogens concavalin A and
LPS) was measured in Young and Old controls and Old-AT groups, and
statistically significant differences between groups were not observed
(results not shown). Migration of spleen leukocytes is represented in
Fig. 5A as the chemotaxis index. Chemotaxis significantly decreased
from Young to Old controls, and this change was totally prevented in
Old-AT mice, which showed values similar to those of Young controls.
Analogously, natural killer (NK) activity of spleen leukocytes decreased
from Young to Old controls, and this change was totally prevented in
Old-AT, which showed values statistically similar to those of Young
control mice (Fig. 5B).
Behavior
In relation to sensorimotor abilities, a significant decrease in equilibrium
was observed in Old compared to Young controls, which was totally
corrected in Old-AT animals (Fig. 6A). Motor coordination and muscular
vigor (Fig. 6B,C) were strongly decreased in Old compared to Young
controls. Old-AT mice showed levels of motor coordination and muscular
vigor higher than those of Old controls and lower than those of Young
controls. Old-AT mice showed significantly higher performance of
central rearing in the open-field test and lower defection and urination
behavior in the open-field and holeboard tests than Old controls, while
no significant differences were detected for horizontal activity, self-
grooming behavior, and goal- or non-goal-directed behavior (results not
shown).
Discussion
In this longevity experiment, lifelong treatment of mice with the
b1-blocker atenolol lowered one of the two traits appropriately
correlating with animal longevity, the membrane fatty acid unsaturation
Fig. 3 Protein oxidation, glycoxidation, and lipoxidation indicators in heart
mitochondria from Young control, Old control, and Old atenolol-treated mice.
Values are means  SEM from six animals and are expressed as percentage of
those in the Young controls for each protein modification marker. Control values:
3172  87 (glutamic semialdehyde, GSA); 295  25 AASA, aminoadipic
semialdehyde, AASA); 455  22 (carboxyethyl-lysine, CEL); 692  20
(carboxymethyl-lysine, CML); 805  60 (malondialdehyde-lysine, MDAL). Units:
lmol/mol lysine. a*: significantly different from Young controls; b*: significantly
different from Old controls; **P < 0.01; ***P < 0.001.
(A) (B)
Fig. 4 Amounts of extracellular-signal-regulated kinase signaling proteins in heart
(A) and skeletal muscle (B) of Young control, Old control, and Old atenolol-treated
mice. Values are means  SEM from 4 animals. Units are ratio of protein content/
tubulin. a* : significantly different from Young control; b* : significantly different
from Old control; *P < 0.05; ** P < 0.01.
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degree of heart and skeletal muscle mitochondria, changing their lipid
unsaturation profile toward that present in much longer-lived mammals.
The atenolol treatment also lowered visceral adiposity, decreased
maximum mitROSp from complex I and oxidative, glycoxidative, and
lipoxidative protein damage in both organs, and oxidative damage in
heart mtDNA. It also improved chemotaxis and natural killer activities,
equilibrium, motor coordination, and muscular vigor and totally or
partially prevented the aging-related changes observed for these
parameters. However, neither mean, median, nor maximum longevities
were modified by the treatment when the whole lifespan was
considered. Atenolol increased somewhat the mortality rate only in very
old animals, between 1000 and 1275 days of age. This is interesting
because this is generally consistent with the results of current meta-
analyses in hypertensive human subjects.
In spite of the lowering of oxidative stress and the improvement in
immunity and behavior, the general survival and the median, mean, and
maximum longevity were not modified by the atenolol treatment. A
reason could be the high longevity of the controls of our study, which
reached 3.93 years of maximum and 31 and 32 months of mean and
median longevity, respectively; these values are higher than the best
previously described for the B6D2F1 (C57BL/6xDBA/2N)F1 strain:
25.7 months for median longevity and 3.0 years for the maximum
longevity of the longest-lived mouse (Yamate et al., 1990). The median
(32 months) and maximum (47.1 months) longevities of our control
mice are similar or higher (maximum longevity) than those of the long-
lived mutant AC5KO (C57BL/6Jx129SvJ) mice (33 and 37 months,
respectively), which affect the same Raf/MEK/ERK signaling pathway
activated by atenolol (Yan et al., 2007); therefore, they are also much
longer-lived than their corresponding controls, 25 and 33 months,
respectively, for the controls of AC5KO. In lifelong survival experiments,
increases in longevity are more frequently obtained when the longevity
of the controls is on the low range, but rarely when it is nearer to the
optimum (see Table 1 in Barja, 2013). The difficulty in increasing the
mean lifespan of very long-lived controls is logical because it is difficult to
make more ‘squared’ a survival curve that is already very rectangular,
and in our case, the shape of the control survival curve (Fig. 1)
approaches that situation.
Recently, it was shown that knocking down enzymes of the PUFA
biosynthesis pathways in C. elegans decreases the DBI and PI due to the
same kind of fatty acid differences observed in the interspecies
comparative studies (Naudi et al., 2011), and in our long-life atenolol
study, and that change increases worm longevity (Shmookler Reis et al.,
2011). This demonstrates the existence of a causal relationship between
desaturase/elongase enzymes, membrane unsaturation, and longevity.
Another likely reason why longevity was not increased in our AT-treated
mice is that atenolol acts far upstream from the final fatty acid changes
in the pathway ‘b-receptor-AC-Raf/MEK/ERK signaling to nucleus
changes in PUFA biosynthesis pathways – DBI modification’, compared
to the C. elegans RNAi experiments that directly curtail the expression of
these enzymes. The further upstream from the final targets, the more
likely is that heavy branching and interconnection during cellular
signaling and their metabolic effects will lead to detrimental side effects.
Negative side effects of atenolol during most of the study could have
been compensated by its multiple positive effects observed in our
investigation, leaving global survival finally unchanged. We observed
cardiovascular-linked negative effects of atenolol only at the end of the
lifespan (between 1000 and 1275 days of age), while other possible
negative effects at younger ages could have been unnoticed due to the
particular selection of measured parameters. Finally, it is generally
agreed that many traits rather than a single one must simultaneously and
coordinately change in the right direction in order for (maximum)
longevity to substantially increase (Barja, 2008). This can also help to
explain the lack of lifespan extension observed in the present investi-
gation.
(A) (B)
Fig. 5 Immune function parameters, chemotaxis (A), and natural killer activity (B),
in Young control, Old control, and Old atenolol-treated mice. Values are
means  SEM from 8 animals. a*: significantly different from Young controls; b*:
significantly different from Old controls; **P < 0.01; *** P < 0.001.
(A)
(B)
(C)
Fig. 6 Behavioral sensorimotor abilities in Young control, Old control, and Old
atenolol-treated mice. Equilibrium (A) and motor coordination (B) were assayed
with the wood rod test, and muscular vigor (C) with the tightrope test. Values are
means  SEM from 8 animals. a*: significantly different from Young controls; b*:
significantly different from Old controls; *P < 0.05; *** P < 0.001.
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The lack of changes in longevity with atenolol treatment is in line with
almost all previous studies attempting to retard aging using drugs and
other small molecules. Thus, neither aspirin, antidiabetics including
metformin, resveratrol, and melatonin, nor many other drugs have
consistently demonstrated increases in rodent maximum longevity
(reviewed in Spindler, 2012). Perhaps, the only exception to this could
be rapamycin, which led to modest but consistent 4–14% increases in
maximum longevity (90th percentile survival age) after parallel replica-
tion of the longevity experiment at three institutions (Harrison et al.,
2009). In contrast, many different single-gene mutant mice have shown
up to 40% increases in maximum longevity. Detrimental side effects of
the drugs can be responsible for such difference with the outcome of the
gene-modifying investigations. Perhaps, an analogous approach to that
used in C. elegans could increase longevity in mammals by more directly
down-regulating PUFA biosynthesis enzymes in mice. Previous studies
disrupting the FADS2 gene coding for delta-6 desaturase have resulted
in / viable but sterile mice suffering various pathologies, including
ulcerative dermatitis, splenomegaly, and intestinal ulceration (Stoffel
et al., 2008; Stroud et al., 2009). Perhaps, alternative approaches
leading to strong but not total depletion of the enzymes responsible
for synthesizing highly unsaturated PUFA could help to design useful
tests of the unsaturation-longevity hypothesis in mammals (Pamplona
et al., 1996, 2002).
Interestingly, while writing this manuscript, we were aware that a
very similar study had recently been published (Spindler et al., 2013). In
that study, 36 B6C3F1 male mice received continuously until death other
two b1-blockers, metoprolol and nebivolol mixed in the diet, beginning
the treatment at 12 months of age. The final effect on survival of these
two drugs was approximately 10% and 6.4% increases in median
lifespan, respectively, with no increase in maximum lifespan. Visual
inspection of the survival curves on that study (Fig. S1a,b) suggests to us
that the maximum lifespan of the b1-blocker-treated animals tended
(not significantly) to be somewhat smaller than that of their controls. The
maximum longevity in that study (around 1400 days according to the
figure survival plots) was very near to that obtained in our investigation
(1433 days), and median lifespan was also very similar in both studies,
983 days in the Spindler et al. (2013) study and 967 days in our
investigation. While we consider the results of both studies very similar,
the differences concerning median lifespan and survival could be due to
the various differences in design: use of different mice strains, use of
different b1-blockers, and different doses and ways of administration. In
addition, the drug treatments were started at 12 months of age in the
Spindler et al. (2013) study and at 2 months of age in our case. Most
interestingly, Spindler et al. (2013) found significantly lower body weight
and higher mortality with metoprolol and nebivolol at 1245–1250 days
of age and later and suggested that this was due to mild drug toxicity in
very old mice due to liver aging. This result is strikingly similar to our
detection of a significantly higher mortality with atenolol between 1000
and 1275 days of age, which would also agree with current meta-
analyses from hypertensive human patients (see below). In our opinion,
the general similarity in the outcome of both studies increases their
reliability, as it means that their results have been generally replicated
independently at two sites in spite of some differences in design.
It is known that atenolol increases human survival after acute
myocardial infarction and prevents premature death in patients with
coronary heart diseases and systolic heart failure. However, meta-analyses
are currently raising the question whether b-blockers (atenolol is the one
most frequently used) are appropriate for the treatment of hypertension
(Lindholm et al., 2005; Cockcroft & Pedersen, 2012). Compared with
other antihypertensive drugs, b-blockers showed higher all-cause
mortality, cardiovascular mortality, myocardial infarction, and heart
failure, especially in association with a lower heart rate. Concerning aged
subjects, the treatment of hypertension with b-blockers has been
questioned in elderly patients (Lindholm et al., 2005), and there is little
information on the possible different effects of atenolol as a function of
age. The negative effects of atenolol can be due to its lowering heart rate,
ineffective lowering or even increase in central aortic pressure, lowered
diastolic pressure, or negative metabolic effects on glucose and lipid
metabolism (Bangalore et al., 2008). In patients with slower heart rate,
the reflected wave from the periphery reaches the next wave in systole
(instead of in diastole) and hence may increase central aortic pressure.
When the survival statistical analysis was restricted to the time
window between 1000 and 1275 days of age, atenolol showed a
significant increase in mortality rate. This shows that atenolol can
increase mortality of a mammal in very old but not in young or middle-
aged individuals, which would be in line with the meta-analyses in
human patients, especially because hypertension is common in old
individuals. This is especially interesting because human hypertensive
patients are usually not medicated until midlife diagnosis but still seem to
show an increased atenolol-induced mortality. We found that 8–13%
decreases in arterial pressures (mean, systolic, and diastolic) and
especially in heart rate (by 20%) occur at the same time window at
which mortality increases in the atenolol group, in very old (35 months
old) animals, but not in young or moderately (18 months) old mice in
which survival is indistinguishable from that of controls. This agrees with
the main change associated with the negative effects of atenolol on
human hypertensive patients, a decrease in heart rate (Bangalore et al.,
2008). Atenolol-induced decreases in heart rate and cardiac output and
transitory peaks of variation of arterial pressure due to poorer pressure
regulation in very old animals, which have a myocardium heavily
degenerated by aging-related damage and the main systemic arteries
stiffened by atherosclerosis, can lead to heart failure and be fatal.
Decreased arterial elasticity would amplify drops in blood flow to critical
main organs including the heart and brain when arterial pressure
variations occur in the downward direction. Such processes are absent
(heart rate and arterial pressures are normal at 18 months of age) or are
better tolerated in younger animals. They could be among the side
effects of the drug counteracting the beneficial effects on oxidative
stress, immune function, and behavior found in this long-life study and
help to explain why longevity was not changed in spite of those benefits.
The chronic atenolol treatment increased the amount of p-ERK,
corroborating activation of the Raf/MEK/ERK signaling pathway, as in
long-lived mutant AC5KO mice (Yan et al., 2007). Neither body weight,
routine metabolic rate, rectal temperature, cardiovascular parameters,
nor mitochondrial oxygen consumption was changed by atenolol in 18-
month-old animals, except for an increase in heart mitochondrial oxygen
consumption with glutamate/malate in state 3 (phosphorylating) in the
Old control group, which was prevented by atenolol. This suggests that,
at least until 18 months of age, the treatment did not promote overt
negative side effects. The lack of modification of total body and organ
weights (except for a decrease in kidney weight) and the absence of
detection of variations in food intake indicate that the many observed
beneficial effects of atenolol are not due to caloric restriction.
Increases in visceral fat in old humans are associated with degener-
ative illnesses, including type 2 diabetes, metabolic syndrome, and
atherosclerosis. Avoiding such increases is considered healthy. In our
study, atenolol provided partial but substantial protection against
increases in visceral fat. The strong age-related increase in visceral fat
from Young to Old controls (424% increase) was 29.5% smaller from
Young controls to Old-AT (299% increase) and 32% smaller when
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expressed as grams of fat per unit body mass. The strong decrease in
visceral adiposity induced by atenolol in Old animals (23.8% decrease) is
also striking because long-term nutritional interventions extending
lifespan in rodents, such as 40% dietary restriction and 80% methionine
restriction (Perrone et al., 2013), also strongly decrease visceral adiposity
per gram of body weight (Malloy et al., 2006) while they induce strong
decreases in growth and final body size. In our case, however, the
lowered visceral adiposity was not accompanied by any detrimental
decreases in body size, similar to what happens in 40% methionine
restriction (Sanchez-Roman & Barja, 2013), although the effect of this
milder intervention on longevity has not been investigated.
The AT treatment did not modify the rate of mitROSp of heart
mitochondria, except for avoidance of an age-related increase in
maximum complex I ROS generation. In the case of skeletal muscle, no
age-related differences inmitROS generationwere observed, and atenolol
treatment decreased complex I mitROSp in Oldmice. This is the respiratory
complex that shows low or decreased mitROS generation in long-lived
species or in caloric-restricted life-extended animals (Barja, 2013). How-
ever, none of the variations inmitROSp observed in either organ are due to
changes in the amount of complex I as revealed by theWestern blots of the
respiratory complexes. Therefore, theymust be due to qualitative complex
I modifications such as those leading to a decrease in the reduction state
and/or the reducing midpoint potential of the complex I ROS generator/s.
In contrast, mtROSp lowering through decreases in complex I content has
been described in dietary or methionine-restricted animals (Sanchez-
Roman & Barja, 2013), although qualitative complex I changes also seem
to be involved in these cases.
There is a negative relationship between the tissue and mitochondrial
degree ofmembrane fatty acid unsaturation and longevity in all the animal
species studied to date (reviewed in Pamplona et al., 2002; Hulbert et al.,
2007; Naudi et al., 2011). This makes the membranes of long-lived
animals highly resistant to lipid peroxidation, because the sensitivity of
fatty acids to lipid peroxidation increases exponentially as a function of the
numberof doublebondspermolecule. In our study, theatenolol treatment
successfully and significantly decreased the global fatty acidmitochondrial
membrane unsaturation measured as the DBI in heart and skeletal muscle
(11% and 22.4%decreases, respectively) and as the PI also in both tissues
(16.8% and 30.8% decreases). These results agree with our short-term
study in total heart tissue of C57BL/6 mice (Sanchez-Roman et al., 2010).
Concerning the intensity of the obtained effect, for example, in skeletal
muscle, atenolol decreased the PI of Old-AT mice to a value similar to that
ofmammalswith a fivefold higher longevity (14.7 years) according to data
in Fig. 7A from Hulbert et al. (2007). Interestingly, the DBI and PI
significantly increased with aging from Young to Old controls (nonsignif-
icant trend for heart DBI), whereas the decrease induced by atenolol
brought back the DBI and PI to values similar to (heart) or even lower
(skeletal muscle) than those of Young mice. Thus, the atenolol treatment
was able to fully prevent all the age-related changes in mitochondrial
membrane unsaturation. The decreases in DBI and PI induced by atenolol
weremainly due to decreases in themost highly unsaturated fatty acid, the
PUFA docosahexaenoic acid (22:6n-3), aided by increases in the MUFA
oleic acid (18:1n-9) in both tissues. Docosahexaenoic acid (22:6n-3) has six
doublebonds and consequently has five bis-allylic hydrogens per chain. It is
320 times more susceptible to ROS attack than oleic acid (18:1n-9;
Holman, 1954; Hulbert et al., 2007).
It is expected that changes in membrane unsaturation would affect
not only the membrane lipids and proteins but also the levels of modified
proteins in cells in general and the mtDNA, which is situated near or
perhaps even in contact with the very abundant inner mitochondrial
membranes. In agreement with that, the five markers of protein
oxidation, glycoxidation, and lipoxidation measured increased during
aging, and all these changes (except for CEL in skeletal muscle) were
totally prevented in Old-AT mice back to the levels shown by Young
animals. It is generally accepted that aging increases protein oxidative
modification, whereas experimental procedures that extend longevity,
such as dietary (Barja, 2013) and methionine restriction (Sanchez-Roman
& Barja, 2013), decrease it. Notably, the strongest age-related changes
were observed for the lipoxidation marker MDAL, which is in agreement
with our previous studies using other longevity-related models.
Concerning mtDNA, in previous short-term studies we have shown
that effectively increasing tissue fatty acid unsaturation by feeding the
animals with the highly unsaturated (n-3) menhaden oil, compared to
diets prepared with saturated fats, increased CML and MDAL in proteins
and notably the 8-oxodG level in mtDNA (and not in the nuclear DNA) of
rat kidney and brain (Pamplona et al., 2004). Nonsignificant trends to 8-
oxodG increases in mtDNA with aging (especially strong in skeletal
muscle) and a significant decrease in 8-oxodG in the heart of Old-AT
mice to values similar to those of Young mice were observed. This agrees
with current models indicating that not only mitROSp, but the
membrane unsaturation degree, can contribute to mtDNA oxidative
damage during aging, likely due to secondary free radicals released by
lipid peroxidation of the very abundant mitochondrial membranes (Barja,
2013). These are situated very near to the sites of mitROSp and to
mtDNA itself, while lipids are scarce in the nucleus, avoiding the
generation of lipid peroxidation products in the vicinity of nuclear DNA.
Age and atenolol treatment also affected important physiological
functions, such as immunity and behavior, similarly to the changes
observed for membrane fatty acid unsaturation and oxidative damage
markers. The capacity for chemotaxis, which allows the migration of
leukocytes toward the inflammatory focus, constitutes one of the first
steps of the immune response, and NK activity is the first line of immune
defense against viral infections and neoplasia. Previous studies in CD1
and BALB/c mice showed that the chemotactic response, the lympho-
proliferative response, and the NK activity were profoundly and
negatively affected by aging in leukocytes from different locations, such
as the peritoneum, thymus, lymphatic nodes, and spleen (De la Fuente
et al., 2004; De la Fuente, 2008). In agreement with those studies, in the
present investigation chemotaxis and NK activity were lower in old
animals than in young ones. These age-related decreases were
prevented by atenolol in Old-AT mice. Atenolol increases various
activities of immune cells in vitro (Guo et al., 2011), but this had not
been described previously in vivo.
The effects of atenolol on the behavioral capacities of mice were
assessed through a wide battery of behavioral tests. Previous studies
have documented age-related impairments in sensorimotor abilities,
motor coordination, and muscular vigor in ICR-CD1 mice (Baeza et al.,
2010). In our lifelong study, aging decreased equilibrium, motor
coordination, and muscular vigor in Old compared to Young controls,
and all these detrimental changes were totally (equilibrium) or partially
prevented by atenolol. In addition, atenolol increased the percentage of
Old mice that performed central rearing in the open-field test. Rearing is
considered the best parameter to estimate non-goal-directed vertical
exploratory activity (Escorihuela et al., 1999) and indicates the interest or
ability of the animal to interact with the environment. Increases in
defecation and urine incontinence also occur in old rodents. The
observed decrease in defecation and urination in Old-AT mice compared
to Old controls indicates a lower anxiety status in these animals. These
results agree with the decreases in anxiety (Deary et al., 1991) and
depression (Al-Tubuly et al., 2008) reported after treatment with
atenolol in human patients.
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In summary, in this study long-term treatment with atenolol
effectively decreased membrane fatty acid unsaturation in mice toward
values typical of much longer-lived animals, lowering visceral adiposity,
decreasing many markers of oxidative stress, and improving immune and
behavioral functions during aging without changing longevity. We
conclude that it is atenolol that failed to increase longevity, and likely not
the decrease in membrane unsaturation.
Experimental procedures
Animals and study design
A total of 134 B6D2F1 (C57BL/6 female 9 DBA/2 male) male mice were
maintained under SPF conditions receiving ad libitum a standard rodent
chow (Panlab, Spain) in individual mouse cages during their whole
lifespan. Eighty-six of these animals (43 Old control and 43 Old-AT-
treated) were used only to obtain the survival curves. The atenolol
treatment started at 2 months of age. Forty-eight separated ‘pilot’
animals were used to measure the different physiological and biochem-
ical parameters at 16 months of age after sacrifice by cervical disloca-
tion. A young control group (6 months of age) was also included.
Atenolol (Sigma, A7655) was given in drinking water at 0.1 g L1, which
resulted in a mean atenolol intake of 0.559 mg per mouse per day. Just
after cervical dislocation, tissues were immediately processed to isolate
functional mitochondria for respiration and mitROS generation mea-
surements. Tissue and excess mitochondrial samples were stored at 80
°C for the posterior analyses. Detailed methods of the physiological
parameters and the measurements in functional mitochondria referred
to below are described in the online Supporting Information.
Physiological parameters
Rectal temperature was measured using a rectal probe, the routine
metabolic rate was measured by closed system respirometry, and heart
rate and blood pressures were measured with a tail-cuff manometer.
Measurements in functional mitochondria
Heart and skeletal muscle mitochondria were obtained at 4 °C from
fresh tissue by differential centrifugation essentially as described in Sanz
et al. (2006). The rate of mitochondrial oxygen consumption was
measured at 37 °C with a Clark-type O2 electrode in the absence (state 4
resting) and in the presence (state 3 phosphorylating) of 500 lM ADP.
The rate of mitochondrial ROS production (O2
 + H2O2, as excess SOD
was added) was assayed by measuring the increase in fluorescence due
to oxidation of homovanillic acid by H2O2 in the presence of horseradish
peroxidase (Sanz et al., 2006).
Measurement of mitochondrial complexes I to IV, apoptosis-
inducing factor, and extracellular-signal-regulated kinase
The amounts of the mitochondrial respiratory chain complexes (I–IV), the
complex I regulatory factor AIF, and ERK1/2 and phospho-ERK1/2 were
estimated using Western blot analyses. Detailed methods are described
in the online Supporting Information.
Fatty acid analyses, their biosynthetic enzymes, and global
fatty acid unsaturation indexes
Fatty acids from mitochondrial lipids were analyzed as methyl ester
derivatives by gas chromatography (GC) as previously described
(Sanchez-Roman et al., 2010). Results are expressed as mol%.
Calculation of the density of double bonds in the mitochondrial
membranes (double bond index, DBI; and peroxidizability index, PI) is
described in the online Supporting Information.
Oxidative damage to mtDNA (8-oxodG)
After isolation, mtDNA was digested to deoxynucleoside level. Steady-
state oxidative damage to mtDNA was estimated by measuring the level
of 8-oxodG referred to that of the nonoxidized base (deoxyguanosine,
dG). 8-OxodG and dG were analyzed by HPLC with online electrochem-
ical and ultraviolet detection.
Oxidation-derived protein damage markers
Glutamic semialdehydes, AASA, CML, CEL, and MDAL in heart and
skeletal muscle mitochondrial proteins were determined by GC/MS with
selected ion monitoring. Detailed methods are described in the online
Supporting Information.
Immune function parameters
The number of leukocytes was determined in cell suspensions obtained
from the spleen. Cellular viability was higher than 95% in all cases.
Lymphoproliferation, chemotaxis (directed migration), and natural killer
(NK) activity assays were performed as referred in the online Supporting
Information.
Behavioral tests
The open-field and holeboard tests were carried out to analyze
exploratory and anxiety-like behaviors. Behavioral tests were performed
as referred in the online Supporting Information.
Statistical methods
Comparisons between the three groups of animals were performed by
one-way ANOVA. Comparison of long-life survival of Old control and
Old-AT-treated animals was analyzed with the log-rank and Wilcoxon
tests. P < 0.05 was selected as the minimum level of statistical
significance.
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Fig. S1 Protein oxidation, glycoxidation and lipoxidation indicators in skeletal
muscle mitochondria from Young control, Old control and Old atenolol
treated mice.
Table S1 Basic physiological parameters in Young control, Old* control, and
Old* atenolol treated mice at 16-18 months of age.
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Table S2 Mean, median and maximum longevities in control and life-long
atenolol-treated mice.
Table S3 Statistical and analysis of total and partial survival curves in control
and life-long atenolol-treated mice.
Table S4 Heart rate and blood pressures in Old control and Old atenolol
treated mice at 35 months of age.
Table S5 Mitochondrial oxygen consumption in Young control, Old control,
and Old atenolol treated mice.
Table S6 Mitochondrial ROS production in Young control, Old control, and
Old atenolol treated mice.
Table S7 Amounts of respiratory complexes and AIF in mitochondria from
Young control, Old control, and Old atenolol treated mice.
Table S8 Fatty acid composition (mol%) of heart mitochondrial lipids of
Young control, Old control, and Old atenolol treated mice.
Table S9 Fatty acid composition (mol%) of skeletal muscle mitochondrial
lipids of Young control, Old control, and Old atenolol treated mice.
Table S10 Oxidative damage in mitochondrial DNA in Young control, Old
control, and Old atenolol treated mice.
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